COMP <GO>
IMDX vs ICCC // PIOTROSKI F-SCORE QUALITY
Insight Molecular Diagnostics Inc. (NASDAQ) VS. ImmuCell Corporation (NASDAQ) • 15-METRIC TALLY: IMDX 4
— ICCC 5
▲ PIOTROSKI F-SCORE QUALITY LEADER: ICCC
LAST: $3.18 (0.00%) • MKT CAP: $104.1M
piotroski-score
4/9
LAST: $10.32 (-2.82%) • MKT CAP: $93.7M
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMDX VS. ICCC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMDX | ICCC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.70% | 41.40% | +15.30 | IMDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 4.20% | -39.20 | ICCC | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 35.9x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -24.38% | 1.31% | -25.69 | ICCC | /fcf-yield <GO> |
| Operating Margin | -60.00% | 6.00% | -66.00 | ICCC | /operating-margins <GO> |
| Net Profit Margin | -1.20% | -3.80% | +2.60 | IMDX | /net-margins <GO> |
| Revenue Growth (YoY) | 115.60% | 4.30% | +111.30 | IMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 4.28 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 8/9 | -4.00 | ICCC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.5 | 50.5 | -8.94 | ICCC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $104.1M | $93.7M | $10.3M | IMDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMDX REV | ICCC REV | IMDX GROSS % | ICCC GROSS % | IMDX FCF | ICCC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.1M | $27.6M | 56.7% | 41.4% | -$25.4M | $1.2M |
| FY 2024 | $1.9M | $26.5M | 39.3% | 30.0% | -$21.2M | -$107.8K |
| FY 2023 | $1.5M | $17.5M | — | — | -$23.3M | -$4.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMDX // BETA —
ICCC // BETA —